Speaker Profile

Ph.D., Founder, Chief Technology Officer, Ontera

William B. Dunbar (Bill) co-founded Ontera Inc. (formerly Two Pore Guys, Inc.) and currently serves as Chief Technology Officer to lead data analysis and IP creation and oversight for Ontera's technologies. Prior to Ontera, Bill was an engineering professor for 12 years at the University of California, Santa Cruz, publishing over 50 peer-reviewed papers and earning the National Science Foundation's prestigious CAREER award. Bill is co-inventor on 20 issued patents on diverse topics, from self-driving cars (owned by Toyota) to nanopore sequencing (licensed by Oxford Nanopore Technologies). Bill invented the dual nanopore device at UC Santa Cruz in 2011, and co-founded Ontera to license and commercialize that IP for applications that include genome mapping, structural variation analysis, epigenetics and long genome sequencing. Bill received a Ph.D. in control and dynamical systems theory from Caltech.

Clinical & Research Tools Showcase:

Ontera's platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point of care testing and third generation sequencing.

Dual-Nanopore Mapping Of Epigenetic Features On DNA
Dual-nanopores are used to capture single DNA and repeatedly scan the molecule to generate electrical signal patterns that can be mined to map labeled sites of epigenetic relevance. Demonstrated labeling applications include base and histone modifications.

 Session Abstract – PMWC 2020 Silicon Valley

Track 6 - January 23 4.30 P.M.-4.45 P.M.,Track 7 - January 24 9.00 A.M.-10.45 A.M.

The PMWC 2020 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.